Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers
Standard
Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. / Sung, Hyuna; Garcia-Closas, Montserrat; Chang-Claude, Jenny; Blows, Fiona M; Ali, H Raza; Figueroa, Jonine; Nevanlinna, Heli; Fagerholm, Rainer; Heikkilä, Päivi; Blomqvist, Carl; Giles, Graham G; Milne, Roger L; Southey, Melissa C; McLean, Catriona; Mannermaa, Arto; Kosma, Veli-Matti; Kataja, Vesa; Sironen, Reijo; Couch, Fergus J; Olson, Janet E; Hallberg, Emily; Olswold, Curtis; Cox, Angela; Cross, Simon S; Kraft, Peter; Tamimi, Rulla M; Eliassen, A Heather; Schmidt, Marjanka K; Bolla, Manjeet K; Wang, Qin; Easton, Douglas; Howat, William J; Coulson, Penny; Pharoah, Paul Dp; Sherman, Mark E; Yang, Xiaohong R.
In: BRIT J CANCER, Vol. 114, No. 3, 02.02.2016, p. 298-304.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers
AU - Sung, Hyuna
AU - Garcia-Closas, Montserrat
AU - Chang-Claude, Jenny
AU - Blows, Fiona M
AU - Ali, H Raza
AU - Figueroa, Jonine
AU - Nevanlinna, Heli
AU - Fagerholm, Rainer
AU - Heikkilä, Päivi
AU - Blomqvist, Carl
AU - Giles, Graham G
AU - Milne, Roger L
AU - Southey, Melissa C
AU - McLean, Catriona
AU - Mannermaa, Arto
AU - Kosma, Veli-Matti
AU - Kataja, Vesa
AU - Sironen, Reijo
AU - Couch, Fergus J
AU - Olson, Janet E
AU - Hallberg, Emily
AU - Olswold, Curtis
AU - Cox, Angela
AU - Cross, Simon S
AU - Kraft, Peter
AU - Tamimi, Rulla M
AU - Eliassen, A Heather
AU - Schmidt, Marjanka K
AU - Bolla, Manjeet K
AU - Wang, Qin
AU - Easton, Douglas
AU - Howat, William J
AU - Coulson, Penny
AU - Pharoah, Paul Dp
AU - Sherman, Mark E
AU - Yang, Xiaohong R
PY - 2016/2/2
Y1 - 2016/2/2
N2 - BACKGROUND: Luminal A breast cancer defined as hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative is known to be heterogeneous. Previous study showed that luminal A tumours with the expression of basal markers ((cytokeratin (CK) 5 or CK5/6) or epidermal growth factor receptor (EGFR)) were associated with poorer prognosis compared with those that stained negative for basal markers. Prompted by this study, we assessed whether tumour characteristics and risk factors differed by basal marker status within luminal A tumours.METHODS: We pooled 5040 luminal A cases defined by immunohistochemistry (4490 basal-negative ((CK5 (or CK5/6))- and EGFR-) and 550 basal-positive ((CK5 (or CK5/6+)) or EGFR+)) from eight studies participating in the Breast Cancer Association Consortium. Case-case comparison was performed using unconditional logistic regression.RESULTS: Tumour characteristics and risk factors did not vary significantly by the expression of basal markers, although results suggested that basal-positive luminal tumours tended to be smaller and node negative, and were more common in women with a positive family history and lower body mass index.CONCLUSIONS: Most established breast cancer risk factors were similar in basal-positive and basal-negative luminal A tumours. The non-significant but suggestive differences in tumour features and family history warrant further investigations.
AB - BACKGROUND: Luminal A breast cancer defined as hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative is known to be heterogeneous. Previous study showed that luminal A tumours with the expression of basal markers ((cytokeratin (CK) 5 or CK5/6) or epidermal growth factor receptor (EGFR)) were associated with poorer prognosis compared with those that stained negative for basal markers. Prompted by this study, we assessed whether tumour characteristics and risk factors differed by basal marker status within luminal A tumours.METHODS: We pooled 5040 luminal A cases defined by immunohistochemistry (4490 basal-negative ((CK5 (or CK5/6))- and EGFR-) and 550 basal-positive ((CK5 (or CK5/6+)) or EGFR+)) from eight studies participating in the Breast Cancer Association Consortium. Case-case comparison was performed using unconditional logistic regression.RESULTS: Tumour characteristics and risk factors did not vary significantly by the expression of basal markers, although results suggested that basal-positive luminal tumours tended to be smaller and node negative, and were more common in women with a positive family history and lower body mass index.CONCLUSIONS: Most established breast cancer risk factors were similar in basal-positive and basal-negative luminal A tumours. The non-significant but suggestive differences in tumour features and family history warrant further investigations.
U2 - 10.1038/bjc.2015.437
DO - 10.1038/bjc.2015.437
M3 - SCORING: Journal article
C2 - 26679376
VL - 114
SP - 298
EP - 304
JO - BRIT J CANCER
JF - BRIT J CANCER
SN - 0007-0920
IS - 3
ER -